Shots:
- The P-lll SURPASS-3 study involves assessing Tirzepatide (5/10/15 mg) vs titrated insulin degludec in 1444 participants in a ratio (1:1:1:1) with T2D treated with metformin with or without an SGLT-2 inhibitor for 52wks.
- The P-lll SURPASS-5 study involves assessing Tirzepatide (5/10/15 mg) vs PBO in 475 participants in a ratio (1:1:1:1) in adults with inadequately controlled T2D already being treated with insulin glargine with or without metformin
- The SURPASS-3 & 5 shows A1C reduction: (-1.93% /-2.20%/-2.37% vs- 1.34%) & (-2.23%/-2.59%/ -2.59% vs -0.93%); Weight reduction: (-8.1%/ -11.4%/-13.9% vs +2.7%) & (-6.6%/-8.9%/-11.6% vs +1.7%) respectively
Click here to read full press release/ article | Ref: PRNewswire | Image: Fortune
The post Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes first appeared on PharmaShots.
